Compare WGO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | TBPH |
|---|---|---|
| Founded | 1958 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.1M | 824.9M |
| IPO Year | 1994 | 2013 |
| Metric | WGO | TBPH |
|---|---|---|
| Price | $27.99 | $16.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $42.78 | $18.40 |
| AVG Volume (30 Days) | ★ 650.7K | 341.5K |
| Earning Date | 03-25-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | 106.82 | ★ 279.13 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,985,674,000.00 | $15,386,000.00 |
| Revenue This Year | $5.10 | $8.46 |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | $76.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.29 | $10.42 |
| 52 Week High | $50.16 | $21.03 |
| Indicator | WGO | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 52.43 |
| Support Level | $27.64 | $16.07 |
| Resistance Level | $35.38 | $17.21 |
| Average True Range (ATR) | 1.09 | 0.30 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 15.20 | 80.63 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.